2,787 reports of this reaction
3.4% of all OFATUMUMAB reports
#6 most reported adverse reaction
INFLUENZA LIKE ILLNESS is the #6 most commonly reported adverse reaction for OFATUMUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 2,787 FDA adverse event reports linking OFATUMUMAB to INFLUENZA LIKE ILLNESS. This represents approximately 3.4% of all 82,579 adverse event reports for this drug.
OFATUMUMAB has an overall safety score of 78 out of 100. Patients taking OFATUMUMAB who experience influenza like illness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFLUENZA LIKE ILLNESS is moderately reported among OFATUMUMAB users, representing a notable but not dominant share of adverse events.
In addition to influenza like illness, the following adverse reactions have been reported for OFATUMUMAB:
The following drugs have also been linked to influenza like illness in FDA adverse event reports:
INFLUENZA LIKE ILLNESS has been reported as an adverse event in 2,787 FDA reports for OFATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFLUENZA LIKE ILLNESS accounts for approximately 3.4% of all adverse event reports for OFATUMUMAB, making it a notable side effect.
If you experience influenza like illness while taking OFATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.